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for thermal and mechanical destruction of tissue, inducing 
coagulative necrosis or subcellular fragmentation, respec-
tively. Preclinical and clinical results of HIFU tumor abla-
tion show increased infiltration and activation of CD4+ 
and CD8+ T cells. As previously observed for other types 
of tumor ablation technologies, however, this ablation-
induced enhanced infiltration alone appears insufficient 
to generate consistent protective antitumor immunity. 
Therapies combining ablation with immune stimulation 
are therefore expected to be key to boost HIFU-induced 
immune effects and to achieve systemic, long-lasting, anti-
tumor immunity.
Keywords High-intensity focused ultrasound · Tumor 
ablation · Immunotherapy · Immune adjuvants · PIVAC 15
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CEA  Carcinoembryonic antigen
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HIFU  High-intensity focused ultrasound
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Abstract Tumor ablation technologies, such as radi-
ofrequency-, cryo- or high-intensity focused ultrasound 
(HIFU) ablation will destroy tumor tissue in a minimally 
invasive manner. Ablation generates large volumes of 
tumor debris in situ, releasing multiple bio-molecules like 
tumor antigens and damage-associated molecular patterns. 
To initiate an adaptive antitumor immune response, anti-
gen-presenting cells need to take up tumor antigens and, 
following activation, present them to immune effector 
cells. The impact of the type of tumor ablation on the pre-
cise nature, availability and suitability of the tumor debris 
for immune response induction, however, is poorly under-
stood. In this review, we focus on immune effects after 
HIFU-mediated ablation and compare these to findings 
using other ablation technologies. HIFU can be used both 
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Introduction
The immune system is able to detect a wide variety of path-
ogens and tumor cells, and to distinguish them from healthy 
host cells. Induction of an adaptive immune response starts 
with phagocytosis of a pathogen by antigen-presenting cells 
(APCs), such as dendritic cells (DCs). The phagocytosed 
antigens are processed into small peptides and presented 
in major histocompatibility complex (MHC) receptors on 
their membranes, after which DCs migrate toward lymph 
nodes (LNs). Further activation signals are required for the 
establishment of a potent immune response, for instance 
via recognition of pathogen-associated molecular patterns 
by pattern recognition receptors (PRR, e.g., Toll-like recep-
tors (TLRs)). DCs subsequently upregulate co-stimulatory 
molecules, including CD40 and CD80, and present the 
foreign antigen to T lymphocytes for recognition by their 
T cell receptors, inducing differentiation of effector and 
memory CD4+ and CD8+ T lymphocytes. These cells then 
perform their effector functions in a concerted manner to 
eliminate pathogen-infected cells or tumor cells.
In cancer patients, lymphocyte-mediated immunity has 
failed to prevent primary tumor development. Poor recogni-
tion of tumor cells by APCs and the lack of proper activa-
tion of these APCs by tumor cells hamper the generation of 
effective immune effector cells. Also, the presence of immu-
nosuppressive cytokines and that of suppressive tumor-
associated cells are common mechanisms by which tumors 
block the induction and establishment of effective CD8+ 
cytotoxic T lymphocytes (CTLs) or CD4+ T helper cells. 
Over the last few years, however, boosting the immune sys-
tem through T cell checkpoint blockade, adoptive T cell 
transfer or vaccination is emerging as an effective treatment 
modality with clinical benefit for cancer patients [1].
Surgical resection of the primary tumor is still the 
mainstay of treatment for many cancer patients. However, 
depending on the tumor type and location of the tumor 
in the body, this procedure can have severe risks for the 
patient. During the last few decades, there has been wide-
spread interest in the development and refinement of abla-
tion techniques for local treatment of tumors in a minimally 
invasive manner. In addition, due to the development of 
imaging modalities and devices, image-guided tumor abla-
tion is increasingly used for curative treatment, as well 
as palliative pain treatment. Ablation in its many forms is 
an attractive alternative treatment option, including for 
patients otherwise ineligible for surgical resection [2, 3]. 
Furthermore, tumor debris remaining in situ after abla-
tion may function as an unbiased source of tumor antigens 
available to the immune system [4]. Possibly, the tumor 
debris could be used to create an in situ cancer vaccine able 
to stimulate systemic immune responses toward (micro)
metastases already present elsewhere in the body, the so 
called abscopal effect [5].
The majority of tumor ablation modalities apply energy 
to cause spatially localized necrosis of tumor cells. Radi-
ofrequency ablation (RFA), microwave ablation (MWA), 
laser ablation (LA) and high-intensity focused ultrasound 
(HIFU) employ different sources of energy to rapidly (in 
seconds or minutes) heat the target region, while cryoab-
lation uses longer (in minutes) cycles of freezing to cause 
cell death. Complete destruction of the tumor by ablation 
techniques has several technical difficulties, such as loss 
of accuracy by respiratory motion or insufficient detection 
of the tumor borders with different imaging modalities. 
Incomplete destruction may also occur due to tissue inho-
mogeneities and asymmetrical heat conduction (heat sink 
effect). Specifically for HIFU, the presence of gas or bone 
in the acoustic field results in scattering or absorption of 
acoustic waves at these interfaces.
HIFU is the only completely noninvasive ablation tech-
nique available to date and has been applied for the treat-
ment of uterine fibroids and prostate, breast, liver, kidney, 
bone and brain tumors [6, 7]. HIFU-mediated ablation 
Fig. 1  Principles of high-inten-
sity focused ultrasound a HIFU 
ablation employs a transducer, 
which creates ultrasound beams 
focused to a single focal zone. 
The acoustic energy increases 
near the focal zone. b This 
energy can be used to generate 
ellipse-shaped thermal or non-
thermal lesions in tumors in a 
noninvasive manner
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makes use of a multi-element ultrasound transducer, posi-
tioned outside the body or in a cavity, to produce high-
intensity ultrasound beams focused to a small region. As the 
ultrasound beams travel toward the focal zone, the conver-
gence of the acoustic waves leads to an increase in energy 
density (Fig. 1). In the focal zone, this energy is absorbed 
by the tissue, elevating temperatures to 60–85 °C in a few 
seconds. The high temperatures in the focus area lead to 
coagulation of proteins and fusion of cell membranes, caus-
ing necrosis of tumor cells. Heat diffusion leads to a tem-
perature gradient outside the focal zone, where cells do not 
receive an instantly lethal thermal dose, but are exposed to 
temperatures over 40 °C. This transition area contains cells 
suffering from thermal stress. In the days following treat-
ment, the majority of these cells have undergone apoptosis 
[8]. A similar pattern is observed with RFA, where in the 
transition zone, defined as the area where cells are exposed 
to temperatures between 40 and 60 °C, a peak in apopto-
sis due to hyperthermia-induced mitochondrial damage or 
impaired membrane function is seen 2 h after treatment [9]. 
With HIFU, the created lesion is normally ellipse-shaped in 
the range of a few millimeters. Ablation of larger volumes 
is therefore achieved by scanning the focal zone through 
the tumor volume, mechanically or electronically, thereby 
treating the entire tumor. Real-time visualization of the 
treatment is performed by either B-mode ultrasound imag-
ing, or magnetic resonance (MR) thermometry [10, 11].
In addition to thermal destruction, HIFU can be used 
to generate non-thermal effects for disruption of tissue, 
known as (boiling) histotripsy [12]. Histotripsy and boiling 
histotripsy are achieved using very short (micro- or mil-
lisecond long) acoustic pulses of high intensity (>5 times 
as high compared to thermal ablation), repeated with a low 
duty cycle to limit temperature increase. For histotripsy, 
these high-pressure waves produce changes in the gaseous 
components in tissues, as bubbles will start to oscillate and 
burst, causing mechanical damage to tissues at a subcellu-
lar level [13]. Boiling histotripsy, which has been applied in 
mice, uses the formation of a millimeter-sized boiling bub-
ble for mechanical disruption of tissues. The created lesion 
is very homogeneous, with no visible cellular components, 
and appears with a sharply demarcated border (<200 µm) 
between vital and fragmented tissue [8]. For more informa-
tion on the physical and technical aspects of mechanical 
HIFU, we refer the reader to [12] and [14].
Poor detection of tumor borders using current imaging 
techniques and/or outgrowth of micrometastases present 
prior to ablation elsewhere in the body can lead to incom-
plete elimination of tumor cells. Local recurrence and dis-
tant metastases are currently also major limitations of abla-
tion modalities [10, 15], and these limitations are shared 
with conventional surgical excision. In this context, it has 
been proposed by us and others to initiate and/or boost 
ablation-induced antitumor immune responses by using 
immunomodulatory agents [16, 17].
Next to lowering the general tumor burden, ablation 
releases tumor antigens and multiple bioactive molecules 
such as damage-associated molecular patterns (DAMPs). 
Combined with general inflammation and immune-regu-
latory processes of the wound healing response following 
ablation, this will result in different innate and adaptive 
immune effects. However, without co-exposure of antigen-
loaded APCs to potent stimulation signals, responses gen-
erally remain weak. Potent antitumor immunity therefore 
is rarely generated, as also evidenced by scarce reports of 
spontaneous regression following ablation [18, 19]. Com-
bining ablation with immunomodulatory adjuvants there-
fore holds great promise, as providing additional stimuli 
can overcome immune tolerance and induce DC and T cell 
activation toward tumor antigen-expressing cells [20]. This 
concept has been reviewed extensively for RFA, cryoabla-
tion and other thermal ablation therapies [21, 22].
HIFU is a relatively new treatment modality with high 
potential. This review aims to summarize the immune 
effects after thermal and mechanical HIFU tumor ablation. 
Furthermore, we will describe parallels with other ablation 
methods and discuss the future perspectives of combination 
treatments with ablation to generate effective antitumor 
immunity.
HIFU‑generated tumor debris
Tumor antigens
HIFU ablation of tumor cells will lead to either coagula-
tive necrosis (i.e., thermal HIFU) or subcellular fragmenta-
tion (i.e., mechanical HIFU). The resulting depot of dam-
aged tumor cells will remain in situ, and tumor antigens 
present in this depot can be captured by tissue-resident 
phagocytic cells, such as DCs, that subsequently migrate 
toward tumor-draining lymph nodes (TDLNs). Alterna-
tively, tumor antigens may passively enter the circulation 
or lymphatics and be transported to LNs where they can be 
taken up by LN-resident DCs. The in situ tumor debris will 
contain all tumor antigens in a (partially) denatured or non-
denatured state, depending on the temperatures reached in 
the focal zone. It has been shown in a cryoablation model 
that the presence of the depot is essential for the creation of 
tumor-specific immune responses. There, protection against 
a rechallenge with the same tumor was attenuated when the 
tumor debris was excised shortly after ablation, indicating 
the importance of release of antigens from the depot [23]. 
Additionally, CT26 colon adenocarcinoma-bearing mice 
treated with RFA followed by surgical excision (1 week 
apart) showed a significantly delayed tumor outgrowth 
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after rechallenge 150 days later, compared to non-tumor-
experienced naïve mice inoculated with the same tumor 
cell dose [24]. Also after RFA and cryoablation of B16 
melanomas in mice, it has been observed that DCs are able 
to readily internalize tumor antigens from the tumor depot 
during the first 2 days, with around 10 % of DCs present 
in LNs becoming positive for the tumor-derived antigen 
[25]. These data indicate that the presence of tumor debris 
is necessary to evoke an antitumor immune response and 
that ablation is effective in obtaining antigen-loaded DCs 
in TDLNs.
The goal of personalized cancer therapy hinges on the 
discovery of suitable antigens giving rise to epitopes pre-
sent in an individual tumor for the creation of tumor vac-
cines, recently coined as the HLA ligandome [26]. These 
vaccines can contain mutated neoantigens, overexpressed 
self-antigens or tissue-specific proteins for cell types not 
essential for survival of the patient. In the last few years, 
several studies have emphasized the importance of rec-
ognition of tumor-mutated neoantigens by immune cells 
[27, 28]. Tumors that are considered as highly immuno-
genic (i.e., melanoma and lung cancer) have higher rates of 
somatic mutations, which lead to additional recruitment of 
neoantigen-specific immune cells [29]. Furthermore, CD8+ 
tumor-infiltrating lymphocytes reactive to clonal tumor 
neoantigens were identified in early stage non-small cell 
lung cancers. More strikingly, T cells recognizing clonal 
neoantigens were detected in patients with good clinical 
outcomes, while poor responders showed enrichment of T 
cells recognizing only subclonal neoantigens. These data 
suggest that immune cells targeting clonal neoantigens play 
a key role in antitumor protection [30]. In principle, in situ 
tumor destruction techniques will create an unbiased tumor 
antigen source in which all types of antigens are present, 
including mutated neoantigens.
Few studies have investigated the presence of tumor 
antigens in HIFU-generated tumor debris by making use 
of mAbs recognizing tumor antigens. One such study dem-
onstrated that in several breast cancer patients, some tumor 
markers, such as CD44v6 and matrix metalloproteinase-9, 
were completely absent in immunohistochemically stained 
tumor biopsies after thermal HIFU ablation, while other 
tumor antigens could be detected to varying degrees in 
the HIFU-induced lesion [31]. A common difficulty of 
antibodies detecting these antigens is the variation in their 
specificity, and the degree in which they recognize (par-
tially) denatured tumor antigens. Following RFA of colo-
rectal liver metastases, patients show an initial increase of 
carcinoembryonic antigen (CEA, a tumor antigen), while 
after surgical resection, the levels of CEA drop rapidly due 
to elimination of the tumor load. After the initial increase 
following RFA, levels of CEA slowly drop to back-
ground levels over time. This suggests a gradual release 
of tumor antigens from the in situ depot into the circula-
tion, which can subsequently be taken up by immune cells 
[32]. Another issue in comparing data from the different 
HIFU studies is the lack of detail in treatment descrip-
tion (see also Table 1). More research is needed using 
detailed HIFU protocols to elucidate the nature of tumor 
antigens present in the debris after thermal and mechani-
cal HIFU ablation and the kinetics of their release into the 
circulation.
Danger signals
After thermal ablation, a lesion of coagulative necrosis 
is formed, as well as a transition zone of cells undergo-
ing apoptosis at a slower rate due to heat stress [33, 34]. 
On the other hand, mechanical HIFU ablation leads to 
cellular fragmentation with only a minimal temperature 
increase [35, 36]. There have been many studies trying to 
correlate the type of in vivo cell death to immunogenic-
ity, and the current consensus is that both apoptosis and 
necrosis can be immunogenic, depending on the release of 
factors such as calreticulin or heat-shock proteins (HSPs) 
[37, 38]. At present, the occurrence of such factors and 
the resulting immunogenicity are still poorly defined for 
the various HIFU treatments. PRRs on the cell surface of 
innate immune cells, such as the highly conserved TLRs, 
are able to discern microbial molecular patterns. How-
ever, TLRs are also able to bind a range of endogenously 
derived self-molecules released in response to cellular 
damage, known as DAMPs. The binding of DAMPs to 
PRRs on innate immune cells promotes intracellular sign-
aling cascades, leading to the production of inflammatory 
cytokines, chemokines and type 1 IFNs. These factors reg-
ulate inflammatory responses and coordinate the develop-
ment of immunity or tolerance to the antigens present [39]. 
Ablation itself will lead to a physiological wound heal-
ing response as a consequence of internal injury. Wound 
healing is a complex phenomenon comprised of different 
discrete stages, each predominated by different cytokines 
and cell types. Some of the initial stages appear more 
inflammatory, while the tissue regeneration stage involves 
immune-regulatory cytokines, like TGF-β, that may be 
more anti-inflammatory or immune suppressive. In conclu-
sion, ablation results in the release of a pleiotropic mix-
ture of signals, including immune stimulatory and immune 
inhibitory signals.
So far only a limited number of studies have investigated 
the release of immune stimulatory signals following HIFU 
ablation. Thermal or mechanical HIFU treatment of MC-38 
colon adenocarcinoma cells in vitro resulted in a rapid 
release of endogenous DAMPs, such as HSP-60 and ATP, 
from the damaged tumor cells [40], from which the latter 
can act as chemoattractant for DCs [41]. Subsequently, 
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in vitro incubation of DCs or macrophages with this super-
natant resulted in an upregulation of co-stimulatory mol-
ecules on their surface (CD80 and CD86), as well as 
an increased secretion of IL-12 by DCs and an elevated 
secretion of TNF-α by macrophages. The stimulatory 
effect was more pronounced by mechanical HIFU treat-
ment compared to thermal HIFU treatment [40]. In addi-
tion, it was shown that HIFU could induce HSP-70 and 
HSP-27 expression in vitro [42, 43]. These results are 
extrapolated to the in vivo situation, where the ongoing 
wound healing response is present, confirming the upreg-
ulation of HSP-70 in the skin of mice after thermal HIFU 
treatment [44]. Clinical evidence demonstrates upregula-
tion of HSP-27, HSP-72 and HSP-73 after HIFU treat-
ment in prostate cancer [43, 45]. This upregulation was 
specifically seen at the border zone of the HIFU-induced 
lesion [45]. In breast cancer patients treated with thermal 
HIFU, HSP-70 was found to be upregulated in the tumor 
debris [31]. These results are similar to results obtained 
from other ablation methods, where RFA-treated B16 
melanomas became highly positive for HSP-70 and gly-
coprotein 96 (gp96) [46]. Similarly, Haen et al. also dem-
onstrated a significant systemic release of HSP-70 into 
the serum one day after RFA treatment of lung, liver and 
kidney malignancies [47]. Furthermore, they observed a 
better clinical outcome in the group with significant HSP-
70 release compared to the group without increase in 
HSP-70 serum levels. However, this was investigated in 
a small cohort with large variation, so these findings need 
to be confirmed in independent studies [47]. Most studies 
looking for HIFU-induced DAMP release have focused 
on HSPs, future investigations should include a broader 
range of DAMPs, and need to define the impact of these 
individual factors on the immunological outcome. Fur-
thermore, the release and the effect of immune inhibitory 
signals following ablation should also be examined.
In conclusion, tumor ablation will lead to formation 
of an in situ antigen depot containing all tumor antigens, 
including mutated neoantigens, which can be processed 
and presented by APCs. Furthermore, ablation will lead to 
the release of DAMPs that potentially could activate cells 
from the innate immune system, such as DCs. However, 
the kinetics of release of tumor antigens and DAMPs from 
the depot after thermal or mechanical HIFU require further 
investigation. In current HIFU literature, however, compari-
sons between different HIFU treatments are complicated by 
lack of details in the treatment description, as well as clas-
sification of the acoustic field generated and the temperature 
in the lesion (see also Table 1). Definition of the molecular 
fingerprint of different ablation approaches may help to pre-
dict whether the ablation-induced inflammation will lead to 
tolerance or a productive antitumor immune response.
HIFU‑induced immune effects
Experimental evidence
Despite the reported enhanced presence of key immu-
nological correlates following ablation, strong immune 
responses have not been observed after tumor ablation as 
monotherapy. Possibly, ablation-induced immunological 
activation and wound healing responses, triggered within 
the same time frame, serve more to regulate and main-
tain immunological tolerance toward the damaged tissue. 
Increasing evidence indicates that HIFU-induced tumor 
ablation can modulate antitumor immunity (summarized 
in Table 1). Zhang and colleagues investigated, using H22 
hepatocellular carcinoma (HCC) bearing mice, whether 
tumor debris could be an effective vaccine to elicit tumor-
specific immune responses [48]. The HIFU-generated 
tumor vaccine significantly increased CTL cytotoxic-
ity and induced enhanced activation of immature DCs. 
Mice immunized with the HIFU-generated tumor vac-
cine showed inhibited tumor growth after a subsequent 
H22 tumor challenge compared with control mice. Simi-
larly, lysate from thermal HIFU-treated H22 tumors was 
shown to induce maturation of DCs [49]. Injection of DCs 
loaded with HIFU-ablated tumor into naïve mice resulted 
in increased CTL cytotoxicity and inhibited tumor growth 
of a H22 tumor challenge compared to controls [49]. 
Alternatively, tumor eradication by thermal HIFU treat-
ment was shown to significantly reduce tumor growth of 
rechallenged tumors in a neuroblastoma model [50]. Fur-
thermore, thermal HIFU ablation of H22 HCC tumors 
resulted in increased cytotoxicity of CTLs, along with a 
significant increase in IFN-γ and TNF-α secretion, com-
pared to untreated controls [51]. Additionally, a signifi-
cant increase in the number of tumor-specific CTLs in the 
HIFU-treated cohort was seen. Adoptive transfer of these 
HIFU-activated CTLs was shown to evoke potent antitu-
mor immune responses in tumor-bearing mice in terms of 
survival benefit and tumor regression [51]. Similar results 
regarding CTL activation were obtained from mice bear-
ing B16F10 melanomas and MC-38 colon adenocarci-
nomas [52, 53]. Interestingly, mechanical HIFU ablation 
of B16F10 tumors was slightly more potent in activat-
ing CTLs compared to thermal HIFU ablation [53]. Fur-
thermore, HIFU treatment, thermal and mechanical, of 
MC-38 adenocarcinomas resulted in enhanced infiltration 
of CD11c+ DCs into tumors and subsequent migration to 
TDLNs [52]. Again, these effects were more pronounced 
in mechanical HIFU-treated mice compared to thermal 
HIFU-treated mice [52]. Mechanical HIFU ablation of 
RM-9 prostate tumors followed by resection 2 days later 
resulted in increased numbers of CD8+ cells in spleens 
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and TDLNs, and these cells exhibited higher tumor-spe-
cific cytotoxicity. The cumulative survival of this dual 
treatment cohort was found to be statistically higher than 
that in the surgery group [54]. These effects are similar 
to several studies using RFA treatment, where increased 
numbers of tumor-reactive CTLs were observed 24 h after 
RFA treatment, with increased CD3+ cells infiltration in 
the transition zone (reviewed in [22]). For thermal HIFU, a 
treatment regime where each thermal lesion does not over-
lap with its neighbors has been recommended, as it has 
been shown that DCs accumulate mostly in the periphery 
of a lesion, where tumor cells are exposed to temperatures 
of <55 °C [55]. This observation implies that sparse-scan 
thermal treatment regime could be more potent in stimulat-
ing immune effects, indicating the importance of optimiza-
tion of the HIFU scan strategy for optimal tumor ablation 
and stronger immune responses.
Taken together, these data suggest that HIFU ablation 
alone does significantly influence the immune system, but 
that the overall antitumor immune response is insufficient. 
Therefore, it has been suggested that different immune 
stimuli can help boost ablation-induced immune effects. 
For cryoablation, it is known that in vivo proximity of 
tumor antigen and immune stimulus (in these studies; 
TLR-9 agonist CpG-ODN) in place and time is essential 
for optimal immune activation. Efficacy of cancer immu-
notherapy was strongly increased only when CpG-ODN 
was administered peritumorally immediately after cry-
oablation [56, 57]. Furthermore, a combination strategy 
of cryoablation, adoptive transfer of DCs and CpG-ODN 
resulted in reduced tumor growth, metastasis formation 
and protection against recurrence of Lewis lung carcinoma 
[16].
In the B16 model, RFA and cryoablation have also been 
combined with a checkpoint blockade antibody directed 
against CTLA-4, resulting in increased numbers of tumor-
specific T cells with increased IFN-γ secretion potential, 
and protection against outgrowth of tumor rechallenges 
[25]. Later, these results were confirmed in a mouse model 
of prostate cancer [58]. In this latter study, cryoablation of 
primary tumors alone also did not affect growth of second-
ary tumors. Systemic effects were only achieved by com-
bining cryoablation with CTLA-4 blockade, which led to 
high infiltration of CD4+ and CD8+ T cells, as well as an 
increase in effector T cell/regulatory T cell ratio in second-
ary tumors [58]. Analyses of the effect of multiple other 
adjuvants in combination with ablation have implicated 
saponins, a new class of non-microbial adjuvants, as being 
particularly potent [17]. The data have shown that saponins 
combine effectively with cryoablation, leading to more effi-
cient uptake of tumor antigens by CD11c+ DCs in TDLNs, 
enhanced cross-presentation and activation, compared to 
cryoablation alone [17].H
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Clinical evidence
As shown in Table 2, clinical results also reveal modula-
tion of the immune system after thermal HIFU ablation. 
Mechanical HIFU tumor ablation has not yet been per-
formed in a clinical setting. So far, several patients with 
various solid malignancies, who had an abnormal CD4+/
CD8+ T cell ratio prior to HIFU treatment, had their CD4+/
CD8+ ratio revert to normal 1 week after ablation [59, 
60]. In a different study, ten out of 15 patients with late-
stage pancreatic carcinomas showed significantly increased 
NK cell activity after HIFU treatment, as well as a trend 
toward more CD3+ and CD4+ cells in peripheral blood was 
observed [61]. Thermal HIFU ablation has also been shown 
to increase the infiltration of DCs, macrophages and CD3+, 
CD4+ and CD8+ lymphocytes in the margins of induced 
lesions in breast tumors, compared with untreated tumors 
[62, 63]. These systemic cellular effects are only present in 
a subset of patients, and effective tumor-specific immune 
responses are not observed. These results are comparable to 
preclinical data, where increases in immune cell infiltration 
and activation can be seen after HIFU treatment.
Evaluation of immune-related cytokines showed 
increases in the Th2 cytokines, IL-6 and IL-10, in serum 
after ablation, although it was not determined what cell 
type secretes these cytokines [64, 65]. The increase in 
IL-6 and IL-10 in plasma levels was observed within 48 h 
using different ablation techniques, where cryoablation 
induced greater changes than heat-based ablation [65]. On 
a serum level, a significant decrease in the immunosuppres-
sive cytokines, including vascular endothelial growth fac-
tor (VEGF), TGF-β1 and -β2, was measured after HIFU 
treatment in patients with various solid malignancies, sug-
gesting that HIFU may reduce immunosuppression [66]. 
In a retrospective study, RFA treatment of colorectal can-
cer liver metastases increased T cell infiltration, as well 
as PD-L1 expression in primary colon tumors [67]. The 
authors confirmed these findings in a CT26 tumor-bearing 
mouse model. Furthermore, they observed that while RFA 
of a tumor can induce strong T cell responses in the distant 
tumors, these tumors quickly overcame this by inhibiting 
T cells via upregulation of PD-L1/PD-1 expression. In this 
setting, combining RFA with anti-PD-1 antibodies showed 
stronger T cell responses and resulted in significantly pro-
longed survival of the tumor-bearing mice [67].
In conclusion, immune effects after tumor ablation 
alone consist mostly of increased infiltration of immune 
cells, including innate and adaptive immune cells, in the 
destroyed tumor tissue, which is observed in experimen-
tal and clinical setup. In several murine tumor models, 
enhanced DC and CTLs activities are observed. In man, the 
results revealed mainly changes in the secretion of inflam-
matory, as well as immunosuppressive cytokines. Systemic 
protection after HIFU has not been observed frequently, 
which is in line with studies using cryoablation or RFA. 
There, systemic effects were only achieved when ablation 
was combined with immune adjuvants, including check-
point blockade antibodies.
Conclusion and perspectives
HIFU is an important development toward a completely 
noninvasive ablation treatment. Thermal and mechanical 
HIFU ablation is being used in various pre-clinical settings 
for different solid malignancies. Thermal HIFU ablation 
is applied in various clinical settings, while for mechani-
cal ablation the first clinical trial is being performed. 
Although preliminary data do suggest that immune effects 
occur after HIFU ablation, such as increased infiltration 
and cytotoxicity of CTLs, no potent tumor-specific immu-
nity has yet been convincingly demonstrated. Despite the 
obviously changing immunological parameters, the minor 
decreases in tumor growth after rechallenge, and incon-
sistent decrease in metastasis formation after HIFU alone, 
do not support the induction of strong antitumor immune 
responses. Data retrieved from HIFU studies so far are in 
line with other ablation technologies and strengthen the 
notion that ablation should be combined with immunomod-
ulatory adjuvants to boost antitumor immune responses. 
Combination strategies could lead to an in situ tumor vac-
cine, where tumor antigens are released from the tumor 
debris and taken up by APCs, while the immunotherapeu-
tic compound helps activate immune cells and overcome 
immunosuppression. Only in such a scenario, long-lasting 
systemic immunity against the tumor can be expected. 
Further studies will elucidate by what mechanism HIFU 
induces or enhances immune responses and what immu-
nomodulatory adjuvants synergizes best with each type of 
ablation in different cancer types. Selecting the best abla-
tion-immune stimulation combination will be key to boost 
HIFU-induced immune effects and to achieve consistent 
protective antitumor immunity.
The effects of tumor ablation are multifold: (1) the 
destruction of tumor mass, lowering tumor burden and 
(2) the release of tumor antigens, making them available 
for uptake by APCs. The treatment itself will lead to (3) 
the release of DAMPs and (4) the induction of a physi-
ological wound healing response. Ablation will lead to 
creation of an in situ antigen depot containing all types 
of tumor proteins. Ablation of tumors at temperatures 
above 65 °C leads to denaturation of proteins. This can 
affect immune responses in opposing ways as high tem-
peratures denature immune activating signals, such as 
danger signals like HSPs, as well as immune suppressive 
signals such as TGF-β or IL-10. Depending on the tumor 
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microenvironment, it may be more important to remove 
immune suppressive signals or maintain danger signals 
using, respectively, thermal ablation or mechanical abla-
tion. Furthermore, availability of tumor antigens from 
the tumor debris may be different between thermal and 
mechanical HIFU. The state of blood vessels in/near the 
treated area should be considered as well, since the major-
ity of immune cells will reach the induced lesion via the 
circulation. More experiments looking closely at the opti-
mal treatment regime for a given cancer patient are needed 
to achieve this. In current literature, however, the treatment 
description, as well as classification of the acoustic field 
generated, is often lacking details (see also Table 1). Fur-
thermore, it is important to know the temperatures reached 
and whether a more sparse- or dense-scan treatment is 
used. A standardized framework of treatment descrip-
tion, such as proposed previously, could facilitate com-
parisons of different HIFU settings and their effects on the 
immune system [68]. Recently, the first animal models for 
mechanical HIFU have been developed [8]. Some murine 
studies suggest that mechanical HIFU induces a stronger 
anti-tumor immune response than thermal HIFU [52, 53]. 
However, studies describing mechanical HIFU are limited, 
underscoring the need for further investigation. Whether 
sequential HIFU conditions exist that are sufficient to trig-
ger potent immune responses in the absence of an adjuvant 
remains to be answered. Furthermore, it will be rewarding 
to look for the best HIFU ablation conditions that can opti-
mally boost immunotherapy and synergize with immune 
adjuvants. Additionally, it will be important to determine 
the relative immunogenicity and nature of HIFU-created 
tumor debris, compared to for instance tumor debris after 
cryoablation or RFA.
In clinical practice, local recurrence of the primary tumor 
and/or emergence of pre-existing metastases are the main 
limitations of successful curative treatment using tumor 
ablation methods. Recent clinical results with current abla-
tion treatments have shown that these problems persist with 
HIFU [10, 15]. To overcome these limitations, it will be key 
to consider combination therapies, combining ablation with 
adjuvants or checkpoint blockade therapy to generate strong 
systemic antitumor immunity for individual patients.
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